Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.
About
TIXiMED is developing TIX100, a first-of-its-kind oral therapeutic that inhibits TXNIP, as a treatment for Type 1 and Type 2 Diabetes, as well as metabolic dysfunction–associated steatotic liver disease (MASLD). The company has successfully completed a Phase 1 clinical study of TIX100 in human subjects. TIX100 is an orally administered novel chemical entity that has shown efficacy in preclinical models and aims to address the underlying causes of diabetes without causing hypoglycemia or weight gain.
Tags
Total Employees
5
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
10Traction
41Team
60Visibility
5Profile
0Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does TIXiMED do?
TIXiMED is developing TIX100, a first-of-its-kind oral therapeutic that inhibits TXNIP, as a treatment for Type 1 and Type 2 Diabetes, as well as metabolic dysfunction–associated steatotic liver disease (MASLD). The company has successfully completed a Phase 1 clinical study of TIX100 in human subjects. TIX100 is an orally administered novel chemical entity that has shown efficacy in preclinical models and aims to address the underlying causes of diabetes without causing hypoglycemia or weight g…
How much funding has TIXiMED raised?
TIXiMED has raised a total of $5M in funding. The most recent round on record is Seed.
Where is TIXiMED headquartered?
TIXiMED is headquartered in Birmingham, Alabama, United States.
When was TIXiMED founded?
TIXiMED was founded in 2021.
What industry does TIXiMED operate in?
TIXiMED operates in Biotechnology, Pharmaceuticals, HealthTech, Medical Devices, Healthcare.
How many employees does TIXiMED have?
TIXiMED has approximately 5 people on record.
Similar Startups